Junior Research Group Leader
Dr. rer. nat. Hannah Uckelmann
Department of Pediatric and Adolescent Medicine
Research Focus: Targeting epigenetic regulators in leukemia development
Contact: uckelmann@med.uni-frankfurt.de
Uckelmann Lab
The Max-Eder Junior research group of Dr. Hannah Uckelmann investigates the epigenetic regulation of self-renewal programs during cancer development with the goal of developing novel targeted therapies. Dr. Uckelmann’s work has significantly advanced our understanding of acute myeloid leukemia (AML), particularly in the context of NPM1 mutations. During her postdoctoral research at Harvard Medical School, she demonstrated the strong efficacy of Menin-MLL inhibitors in NPM1 mutant AML models, laying the groundwork for ongoing clinical trials. Her group has since uncovered a previously unknown role of mutant NPM1 in shaping chromatin structure, explaining the molecular basis for the therapeutic benefit of Menin-MLL inhibition. Building on these insights, her laboratory now continues in several projects to dissect the mechanisms of NPM1c-driven leukemogenesis and explores innovative therapeutic strategies to improve outcomes for AML patients.
Find out more about the Uckelmann Lab here.
